Back

AIOM 2022 - XXIV National Congress of Italian Association of Medical Oncology

Nov 05 - Nov 07, 2022 | RomeItaly

LARVOL is not affiliated with XXIV National Congress of Italian Association of Medical Oncology and all trademarks, logos, and brand names are property of their respective owners

Top Trials
Top Trials has no data

Showing 44 abstracts linked to Trials

A01 - REAL-WORLD OUTCOMES OF PATIENTS WITH ADVANCED LUNG ADENOCARCINOMA TREATED WITH FIRSTLINE CHEMO-IMMUNOTHERAPY IN ITALY

  • Oral

A09 - OSIMERTINIB IN UNTREATED EGFRMUTANT NON-SMALL CELL LUNG CANCERS: OVERALL SURVIVAL AND BUDGET IMPACT ANALYSIS IN REAL-WORLD

A18 - OSIMERTINIB IN EGFR-MUTANT ADVANCED NSCLC: THE ATLAS MULTICENTRE COHORT STUDY

A27 - BUDGET IMPACT ANALYSIS OF CEMIPLIMAB FOR FIRST-LINE (1L) ADVANCED NONSMALL CELL LUNG CANCER (NSCLC) WITH PROGRAMMED CELL DEATH-LIGAND 1 (PDL1)= 50% IN ITALY

C31 - TRASTUZUMAB DERUXTECAN (T-DXD) IN HER2 POSITIVE (HER2+), ADVANCED BREAST CANCER (ABC): A SINGLE INSTITUTION, REAL WORLD EXPERIENCE

  • Oral

C33 - RISK OF DRUG-INDUCED INTERSTITIAL LUNG DISEASE IN PATIENTS WITH METASTATIC BREAST CANCER TREATED WITH ANTIHER2 REGIMENS: A NETWORK META-ANALYSIS

  • Oral

D24 - SAFETY OF RUCAPARIB AS MAINTENANCE THERAPY AFTER PLATINUM-BASED CHEMOTHERAPY IN PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER: THE REALLIFE EXPERIENCE IN PUGLIA

  • Oral

D39 - AN OBSERVATIONAL, MONOCENTRIC, RETROSPECTIVE ANALYSIS OF MEN WITH NEW DIAGNOSIS OF HIGH-RISK METASTATIC CASTRATION NAÏVE PROSTATE CANCER FOLLOWING ABIRATERONE ACETATE PLUS PREDNISONE AND ANDROGEN DEPRIVATION THERAPY

  • Oral

D41 - PEMBROLIZUMAB AS SECOND LINE TREATMENT IN METASTATIC UROTHELIAL CANCER: A MULTICENTER REAL LIFE STUDY

  • Oral

G05 - SAFETY AND EFFICACY OUTCOMES IN HEAD AND NECK CANCER (HNC) PATIENTS (PTS) TREATED WITH FIRST-LINE (1L) PEMBROLIZUMAB (P), ALONE OR WITH CHEMOTHERAPY (CT)

  • Oral

G06 - PEMBROLIZUMAB ALONE OR WITH CHEMOTHERAPY FOR RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (R/M HNSCC): A SINGLE INSTITUTIONAL RETROSPECTIVE REPORT

  • Oral

S10 - TUMOUR-AGNOSTIC INDICATIONS: ARE WE MOVING TOWARDS A MUTATION-DRIVEN APPROACH IN PRECISION ONCOLOGY?

  • Oral